These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30945330)

  • 1. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
    Tschautscher MA; Jevremovic D; Rajkumar V; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
    Am J Hematol; 2019 Jul; 94(7):751-756. PubMed ID: 30945330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma.
    Ghosh T; Gonsalves WI; Jevremovic D; Dispenzieri A; Dingli D; Timm MM; Morice WG; Kapoor P; Kourelis TV; Lacy MQ; Hayman SR; Buadi FK; Leung N; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust SR; Warsame R; Hwa YL; Kyle RA; Gertz MA; Vincent Rajkumar S; Kumar SK
    Am J Hematol; 2017 Sep; 92(9):E507-E512. PubMed ID: 28568244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
    Bansal R; Baksh M; Larsen JT; Hathcock MA; Dingli D; Stewart AK; Kapoor P; Kourelis T; Hayman SR; Warsame RM; Fonseca R; Bergsagel PL; Ailawadhi S; Kumar SK; Lin Y
    Blood Cancer J; 2023 Apr; 13(1):47. PubMed ID: 37019896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
    Pasvolsky O; Pasyar S; Bassett RL; Khan HN; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Cancer; 2024 May; 130(9):1663-1672. PubMed ID: 38127583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
    Perrot A; Lauwers-Cances V; Corre J; Robillard N; Hulin C; Chretien ML; Dejoie T; Maheo S; Stoppa AM; Pegourie B; Karlin L; Garderet L; Arnulf B; Doyen C; Meuleman N; Royer B; Eveillard JR; Benboubker L; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Kolb B; Fohrer C; Mohty M; Macro M; Richardson PG; Carlton V; Moorhead M; Willis T; Faham M; Anderson KC; Harousseau JL; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H; Munshi N
    Blood; 2018 Dec; 132(23):2456-2464. PubMed ID: 30249784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
    Alonso R; Cedena MT; Gómez-Grande A; Ríos R; Moraleda JM; Cabañas V; Moreno MJ; López-Jiménez J; Martín F; Sanz A; Valeri A; Jiménez A; Sánchez R; Lahuerta JJ; Martínez-López J
    Am J Hematol; 2019 Aug; 94(8):853-861. PubMed ID: 31074033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
    J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
    Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
    [No Abstract]   [Full Text] [Related]  

  • 14. Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
    Kastritis E; Kostopoulos IV; Theodorakakou F; Fotiou D; Gavriatopoulou M; Migkou M; Tselegkidi MI; Roussou M; Papathoma A; Eleutherakis-Papaioakovou E; Dialoupi I; Kanellias N; Ntalianis A; Rousakis P; Trougakos IP; Tsitsilonis O; Gakiopoulou C; Terpos E; Dimopoulos MA
    Amyloid; 2021 Mar; 28(1):19-23. PubMed ID: 32783569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
    Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.
    Kunacheewa C; Lee HC; Patel K; Thomas S; Amini B; Srour S; Bashir Q; Nieto Y; Qazilbash MH; Weber DM; Feng L; Orlowski RZ; Lin P; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e221-e238. PubMed ID: 32037287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
    Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
    Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
    Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.